GALNT6 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL7980209	1.00	1/20
SCHEMBL29370098	1.00	1/20
SCHEMBL26768213	0.79	1/20
SCHEMBL7987277	0.69	1/20
SCHEMBL2357304	0.68	1/20
SCHEMBL29466713	0.68	1/20
SCHEMBL29827270	0.68	1/20
SCHEMBL17949557	0.66	1/20
SCHEMBL7984298	0.66	1/20
SCHEMBL9748319	0.61	1/20
SCHEMBL21517158	0.61	1/20
SCHEMBL3874869	0.61	1/20
SCHEMBL15285080	0.61	1/20
SCHEMBL31414410	0.61	1/20
SCHEMBL7330918	0.60	1/20
SCHEMBL22431062	0.59	1/20
SCHEMBL1444851	0.58	1/20
SCHEMBL30451609	0.58	1/20
SCHEMBL5351976	0.58	1/20
SCHEMBL7227954	0.57	1/20

Clinical trials — most relevant to GALNT6 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry Disease	PHASE4	COMPLETED
A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis	PHASE1/PHASE2	RECRUITING
A Study of GlcNAc on Tear Production in NGLY1-CDDG	PHASE2	ACTIVE_NOT_RECRUITING
Multi-Center Study of ManNAc for GNE Myopathy	PHASE2	ACTIVE_NOT_RECRUITING
A Study to Evaluate the Safety, Tolerability and Efficacy of BMN 110 in Subjects With Mucopolysaccharidosis IVA	PHASE1/PHASE2	COMPLETED
24-Week Study to Assess the PD, Safety, Tolerability, and PK of GLM101 in Participants With PMM2-CDG	PHASE2	COMPLETED
A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases	PHASE1	COMPLETED
Glycosylation in Patients With Galactosaemia	nan	COMPLETED
BMN 110 US Expanded Access Program	nan	APPROVED_FOR_MARKETING
Genome Environment Microbiome and Metabolome in Autism Study	nan	COMPLETED
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML)	nan	WITHDRAWN
A Retrospective Study to Identify New Omics Biomarkers of Chronic/Persistent Low Back Pain	nan	COMPLETED
Inflammatory Pathways and Cardiac Growth Factors Associated With Fabry Disease Cardiomyopathy	nan	UNKNOWN
Institution of an Italian Multicenter Database of Patients Affected by Diseases of Phosphate Metabolism	nan	NOT_YET_RECRUITING
Natural History Study of Participants With Sanfilippo Syndrome Type IIIC	nan	RECRUITING
Using D-Galactose as a Food Supplement in Congenital Disorders of Glycosylation	nan	COMPLETED
Fibrosis, Inflammation, Oxygenation of Renal Tissue In FabrY Disease	nan	RECRUITING
the Role of cArdiac Inflammation, endoThelial Dysfunction, and FIbrosis in fabrY Disease	nan	RECRUITING
Screening of Fabry Disease in Patients With GI Symptoms	nan	UNKNOWN
Registry Gangliosidoses	nan	UNKNOWN
Sialic Acid Supplementation in N-Acetylneuraminic Acid Synthase (NANS) Deficiency	nan	COMPLETED
A Natural History Study of Patients With GNE Myopathy and GNE-Related Diseases	nan	COMPLETED
The Natural History of Alpha-Mannosidosis	nan	COMPLETED
Evaluation of Blood Protein O-GlcNAcylation Levels in Children	nan	RECRUITING
Evaluation of Gastrointestinal Symptoms Following Chilean Native Beans Consumption	nan	UNKNOWN
GNAO1 Natural History Study	nan	UNKNOWN
Natural History of Glycosphingolipid Storage Disorders and Glycoprotein Disorders	nan	RECRUITING
A Prospective Trial to Identify Biomarkers Involved in the Transition From Acute to Persistent Chronic Low Back Pain	nan	UNKNOWN
Clinical Trial Readiness for the Dystroglycanopathies	nan	RECRUITING
Early Detection and Follow-Up of Patients With Fabry's Disease	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a GALNT6 binder may also engage these)

Protein	Name	Similarity
Q5EA41	—	1.000	Q5EA41 →
Q8C7U7	—	1.000	Q8C7U7 →
Q6P6V1	—	1.000	Q6P6V1 →
Q8IXK2	—	1.000	Q8IXK2 →
Q921L8	—	0.999	Q921L8 →
Q6DJR8	—	0.999	Q6DJR8 →
Q9JJ61	—	0.999	Q9JJ61 →
Q8N428	—	0.997	Q8N428 →
H0ZAB5	—	0.997	H0ZAB5 →
Q8MV48	—	0.996	Q8MV48 →
GALNT3	Polypeptide N-acetylgalactosaminyltransferase 3	0.996	landscape →
Q925R7	—	0.995	Q925R7 →
Q8BVG5	—	0.995	Q8BVG5 →
P70419	—	0.995	P70419 →
Q6WV20	—	0.994	Q6WV20 →
Q8BGT9	—	0.994	Q8BGT9 →
O08832	—	0.993	O08832 →
Q8NCW6	—	0.993	Q8NCW6 →
GALNT10	Polypeptide N-acetylgalactosaminyltransferase 10	0.993	landscape →
Q29121	—	0.993	Q29121 →
GALNT14	Polypeptide N-acetylgalactosaminyltransferase 14	0.993	landscape →
Q8CF93	—	0.993	Q8CF93 →
Q9D4M9	—	0.993	Q9D4M9 →
O61394	—	0.993	O61394 →
Q49A17	—	0.992	Q49A17 →
Q6WV17	—	0.992	Q6WV17 →
O08912	—	0.992	O08912 →
GALNT13	Polypeptide N-acetylgalactosaminyltransferase 13	0.992	landscape →
GALNT1	Polypeptide N-acetylgalactosaminyltransferase 1	0.992	landscape →
Q6UE39	—	0.992	Q6UE39 →